Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
S. D. de Boer, M. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-meder, P. Ottevanger, J. Ledermann, P. Khaw, A. Colombo, A. Fyles, M. Baron, H. Kitchener, H. Nijman, R. Kruitwagen, R. Nout, K. Verhoeven-Adema, V. Smit, H. Putter, C. Creutzberg
The Lancet Oncology